Based on the findings of a new study published in Brain, researchers from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London are calling for a complete rethink of the national guidelines surrounding who can access genetic testing for amyotrophic lateral sclerosis (ALS), also called motor neuron disease. The research suggests that there are hundreds of people with ALS in the UK for whom a genetic basis of their ALS is being missed as they do not fit the narrow requirements for genetic testing. As guidelines are similar in many countries, this situation will likely be the same internationally, meaning potentially thousands of people being unaware of a genetic link to their ALS.
ALS is a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing paralysis of muscles. Around 1 in 300 people will be diagnosed with ALS at some point in their lives, with the average person surviving for between two and five years after their symptoms begin. There is currently no cure for ALS.
In some cases, there is an identifiable genetic cause. Given the current restrictive testing guidelines, the researchers wanted to establish the probability of a positive genetic test result in various scenarios to provide evidence for how and when genetic testing should be used. They performed two analyses on global data sets, analysing the four most common ALS genes and a larger panel of 26 ALS genes.
Their analysis revealed that, by limiting testing in those without a family history to people with symptom onset below 40 years, as per current UK guidelines, 115 of 117 positive test results were missed. Extrapolating this data to other health systems across the world, they found that potentially thousands of people with ALS will not know they have a genetic cause of their ALS due to the inaccessibility of testing.
Professor Ammar Al-Chalabi, Professor of Neurology and Complex Disease Genetics at King’s IoPPN, and the study’s lead author, said, “ALS is a condition that destroys lives. Genetic testing means that people and their families can be given correct advice and access to genetic counselling and be supported with family planning. Our study found that there are large numbers of people who are unable to access this care and support because of the arbitrary age limits and rules currently in place.”
While the researchers recognise that expanding the guidelines to include more people will be resource intensive, they argue that, where possible, countries should aim to offer genetic testing to ALS patients of all ages.
Dr Puja Mehta, the study’s first author, said “Our study shows the importance of being able to offer people with ALS of all ages a blood test to identify a possible genetic cause. In addition to accessing appropriate genetic counselling and support, with the exciting prospect of specific gene-based therapies on the horizon, and with clinical trials underway, it will become all the more important for people with ALS to know if they have an identifiable genetic cause.”
Dr Nicholas Cole, Head of Research at the MND Association said: “This research, supported by the MND Association, adds weight to the suggestion that routine genetic testing should be offered to MND patients, regardless of their age at onset or family history of the disease. Genetic testing could provide opportunity for more people with MND to be involved in tailored clinical trials. However, it is imperative that testing is supported by a robust genetic counselling infrastructure to provide tailored support to all those who choose to embark upon this process.
“These findings are thanks to the people with MND who have generously contributed to datasets funded by the MND Association, including ProjectMinE, the UK National DNA Bank for MND Research and the MND Register for England, Wales and Northern Ireland, each of which is accelerating the global effort to find treatments, and eventually a cure for MND.
“Together with our researchers, their support means we are understanding more about this complex disease and helping to focus effort and expertise in the right areas.”
This research was part-funded by the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre.
Ends
For more information, please contact Patrick O’Brien (Senior Media Officer) at 07813706151
The impact of age on genetic testing decisions in amyotrophic lateral sclerosis (doi.org/10.1093/brain/awac279) (Puja R. Mehta, Alfredo Iacoangeli, Sarah Opie-Martin, Joke J. F. A. van Vugt, Ahmad Al Khleifat, Andrea Bredin, Lynn Ossher, Peter M. Andersen, Orla Hardiman, Arpan R. Mehta, Pietro Fratta, Kevin Talbot, Project MinE ALS Sequencing Consortium, and Ammar Al-Chalabi) was published in Brain
About King’s College London and the Institute of Psychiatry, Psychology & Neuroscience
King's College London is one of the top 35 UK universities in the world and one of the top 10 in Europe (QS World University Rankings, 2020/21) and among the oldest in England. King's has more than 31,000 students (including more than 12,800 postgraduates) from some 150 countries worldwide, and 8,500 staff. King's has an outstanding reputation for world-class teaching and cutting-edge research. The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s is the premier centre for mental health and neurosciences research in Europe. It produces more highly cited outputs (top 1% citations) on mental health than any other centre (SciVal 2019) and on this metric we have risen from 16th (2014) to 4th (2019) in the world for highly cited neuroscience outputs. World-leading research from the IoPPN has made, and continues to make, an impact on how we understand, prevent and treat mental illness, neurological conditions, and other conditions that affect the brain.
www.kcl.ac.uk/ioppn @KingsIoPPN
The National Institute for Health and Care Research (NIHR)
The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by:
NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK Aid from the UK government.
Brain
Observational study
People
The impact of age on genetic testing decisions in amyotrophic lateral sclerosis
27-Sep-2022
P.M.A. reports consultancies or advisory boards for Biogen, Roche, Avrion, Regeneron and Orphazyme; is a clinical trial site investigator for Biogen, Alexion, Sanofi, Lilly AL-S Pharma, Amylyx and Orphazyme; is a member of the ClinGen ALS Gene Curation Expert panel and is Director of the ALS genetic laboratory at Umeå University Hospital that performs genetic research and clinical testing, since 1993. O.H. reports consultancies or advisory boards for Cytokinetics and Novartis and is co-chair of ENCALS, a member of the executive of the TRICALS consortium and Editor in Chief of Amyotrophic Lateral Sclerosis & the Frontotemporal Degeneration. K.T. reports consultancies or advisory boards for Roche, WAVE Lifesciences and LifeArc. A.A.-C. reports consultancies or advisory boards for Amylyx, Apellis, Biogen, Brainstorm, Cytokinetics, GSK, Lilly, Mitsubishi Tanabe Pharma, Novartis, OrionPharma, Quralis and Wave Pharmaceuticals. P.C. reports consultancies for Biogen. J.E.L. is a member of the scientific advisory board for Cerevel Therapeutics, a consultant for ACI Clinical LLC sponsored by Biogen Inc. or Ionis Pharmaceuticals Inc. J.E.L. is also a consultant for Perkins Coie LLP and may provide expert testimony. P.V.D. reports consultancies or advisory boards for Biogen, UCB, ArgenX, Muna Therapeutics, Alector, Augustine Therapeutics, Alexion Pharmaceuticals, Ferrer, QurAlis, Cytokinetics and CSL Behring. J.V. reports sponsored research agreements with Biogen.